ArticleMolecular genetics and metabolism reports2024

Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan.

Makoto Arakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.